

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Lee's Pharmaceutical Holdings Limited**

**李氏大藥廠控股有限公司\***

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 950)**

### **VOLUNTARY ANNOUNCEMENT – UPDATE ON AN INVESTIGATIONAL OPHTHALMOLOGY PRODUCT**

This announcement is made by the board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that, on 28 May 2018, the first patient has been enrolled in a Phase II study of the Group’s in-house product, Cyclosporine A Eye Gel for the treatment of dry eye syndrome (the “**DES**”) in China.

This trial designed as a Phase II multicentre, randomized, single-blind, positive controlled and dose finding exploratory clinical trial to evaluate efficacy and safety of Cyclosporine A Eye Gel in treating patients with moderate to severe DES and to explore the optimal dose and frequency of Cyclosporine A Eye Gel in those patients. This trial is led by Professor ZHOU Shi-you from Zhongshan Ophthalmic Centre, Sun Yat-sen University. The study plans to enroll a total of 240 patients assigned to four cohorts. The primary outcome measures of the change of eye dryness score from the baseline after the 12 weeks treatment in each cohort. The first patient of this study has been enrolled on 28 May 2018 and the study is expected to last for one year.

Cyclosporine A Eye Gel is the first and only Cyclosporine A Eye Gel product obtained clinical trial approval in China. This new improved formulation is patent protected with better PK/PD profiles in the preclinical studies compared to the Cyclosporine Ophthalmic Emulsion. This achievement attests the Group’s capability in new drug formulation discovery and development.

According to GlobalData, in 2016, China had the highest number of total prevalent cases of DES with more the 190 million cases and it forecasts that China and the United States will have the largest burden associated with DES over the next decade. Cyclosporine products make up the biggest market share globally with sales of US\$1.4 billion (66.5%) in 2016.

The Group is fully integrated with solid infrastructures in drug development, clinic, perspectives and the Group has established extensive partnerships with over 20 international companies and currently markets 17 proprietary and licensed-in pharmaceutical products in Mainland China, Hong Kong and Macau. The Group focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology, ophthalmology and others. The Group has more than 50 products under different development stages stemming from both internal research and development as well as from the recent acquisition of licensing and distribution rights from various United States, European and Japanese companies.

By order of the Board of  
**Lee's Pharmaceutical Holdings Limited**  
**Lee Siu Fong**  
*Chairman*

Hong Kong, 26 June 2018

*\* For identification purpose only*

*As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simon Miles Ball is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.*